Up next

Bio/Pharma Industry Outlook, Supply Chains 2025: The Year Ahead

Derron Stark, EY-Parthenon Partner, Strategy & Transactions – Health Sciences & Wellness, Supply Chain, Ernst & Young LLP

What will be the key issues shaping bio/pharma supply chains in 2025? Looking at the impact of potential changes in US tariff and trade policy. Plus, what lies ahead in product-specific supply chains for sterile injectables and antibody drug conjugates. And the latest on how companies are advancing upstream supplier risk monitoring and predictive risk planning, including through digitalization and AI.

Featuring: Derron Stark, EY-Parthenon Partner, Strategy & Transactions – Health Sciences & Wellness, Supply Chain, Ernst & Young LLP

Each episode is housed on the DCAT Value Chain Insights website and also delivered through DCAT Value Chain Insights weekly email digest. Not a subscriber? Click here to subscribe to DCAT Value Chain Insights. Or get each episode through:

For a full list of the 2025 podcast episode schedule, click here.

You May Also Like

Drug Launches & Approvals in 2025: The Blockbuster Contenders

By
Which bio/pharmaceuticals, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1 billion or more) in the mid term, and what upcoming launches or approvals and trends should be on the industry’s radar? Matthew Arnold, Principal…

CDMOs-Injectables: Tariff Impact: Are Capacity Shifts in the Making?

By
Sponsored by Vetter Pharma International GmbH What will be the impact of US tariffs on CDMOs of injectables and on the decision-making of pharma companies on in-sourced/outsourced activity overall and…

Headwinds or Tailwinds: Will the Biotech Sector Rebound in 2025? 

By
Biotech companies are an important source for innovation and product development for larger companies and are an important customer base of CDMOs/CMOs. Capital flow in the biotech sector, an important…

Global API Outlook: Will Supply Lines Change Amid Tariff Uncertainty? 

By
As evolving US trade policy looms, what are the demand–supply fundamentals now in the global market for active pharmaceutical ingredients (APIs)?  A look at the demand side—size, growth rates, and…